Holen Sie sich die Stockscreener-App
24.76
3.86%
0.92
Handel nachbörslich:
24.50
-0.26
-1.05%
Schlusskurs vom Vortag:
$23.84
Offen:
$24.28
24-Stunden-Volumen:
1.01M
Relative Volume:
0.72
Marktkapitalisierung:
$5.04B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-464.20M
KGV:
-9.2309
EPS:
-2.6823
Netto-Cashflow:
$-423.09M
1W Leistung:
+4.92%
1M Leistung:
-9.07%
6M Leistung:
+58.01%
1J Leistung:
+36.12%
1-Tages-Spanne:
$24.26
$25.17
1-Wochen-Bereich:
$22.79
$25.17
52-Wochen-Spanne:
$12.72
$29.25
Immunovant Inc Stock (IMVT) Company Profile
Firmenname
Immunovant Inc
Sektor
Branche
Telefon
917-410-3120
Adresse
1000 PARK FORTY PLAZA, DURHAM, NY
Compare IMVT vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
24.76 | 4.85B | 0 | -464.20M | -423.09M | -2.6823 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-20 | Eingeleitet | Bernstein | Mkt Perform |
| 2026-01-06 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-10-14 | Eingeleitet | Truist | Hold |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-03-03 | Eingeleitet | Jefferies | Hold |
| 2025-01-03 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-10-09 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-28 | Eingeleitet | Oppenheimer | Outperform |
| 2024-03-13 | Eingeleitet | Goldman | Buy |
| 2024-02-20 | Eingeleitet | JP Morgan | Overweight |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-13 | Hochstufung | UBS | Neutral → Buy |
| 2023-09-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | Eingeleitet | BofA Securities | Buy |
| 2023-04-25 | Eingeleitet | Citigroup | Buy |
| 2023-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2023-03-30 | Eingeleitet | Stifel | Buy |
| 2023-02-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | Herabstufung | UBS | Buy → Neutral |
| 2021-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-08-03 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-01 | Herabstufung | Stifel | Buy → Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-10-12 | Eingeleitet | Guggenheim | Buy |
| 2020-10-08 | Eingeleitet | Stifel | Buy |
| 2020-10-02 | Eingeleitet | Credit Suisse | Outperform |
| 2020-08-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-07-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-24 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Immunovant Inc Aktie (IMVT) Neueste Nachrichten
LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT - MSN
Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish - AOL.com
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? - AOL.com
Top Immunovant Executive Quietly Cashes Out in Notable Insider Stock Move - TipRanks
Immunovant (NASDAQ:IMVT) Insider Tuyl Christopher Van Sells 2,877 Shares - MarketBeat
Immunovant (IMVT): Chief legal officer Van Tuyl sells $71k in stock - Investing.com
Immunovant, Inc. (IMVT) CLO sells 2,877 shares to cover RSU taxes - Stock Titan
Bernstein initiates Immunovant stock coverage with neutral rating - Investing.com UK
Bernstein initiates Immunovant stock coverage with neutral rating By Investing.com - Investing.com India
Immunovant (NASDAQ:IMVT) Now Covered by Sanford C. Bernstein - MarketBeat
Is Immunovant Gaining Fresh Momentum Across The Nasdaq 100 Index Now? - Kalkine Media
Understanding the Setup: (IMVT) and Scalable Risk - Stock Traders Daily
Immunovant shares climb 7% as fiscal Q3 loss comes in better than expected - MSN
Immunovant, Inc. $IMVT is Alpine Global Management LLC's 3rd Largest Position - MarketBeat
Immunovant, Inc. $IMVT Shares Purchased by Granahan Investment Management LLC - MarketBeat
HighVista Strategies LLC Grows Position in Immunovant, Inc. $IMVT - MarketBeat
Truist Securities Initiates Coverage of Immunovant (IMVT) with Hold Recommendation - MSN
Prosight Management LP Has $11.26 Million Stock Position in Immunovant, Inc. $IMVT - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Immunovant stock surges 17% in 3 months: What's driving it? - MSN
Immunovant, Inc. (IMVT) analysts raise price targets following Q3 earnings update - MSN
Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence - MSN
The Technical Signals Behind (IMVT) That Institutions Follow - Stock Traders Daily
UBS Downgrades Immunovant (IMVT) - MSN
Immunovant Stock Surges 17% in 3 Months: What's Driving It? - TradingView
Immunovant Stock Pre-Market (+8.1%) : Key Analyst Upgrade Cites Pipeline Confidence - Trefis
Vanguard Group Inc. Has $110.05 Million Holdings in Immunovant, Inc. $IMVT - MarketBeat
TD Asset Management Inc Sells 56,752 Shares of Immunovant, Inc. $IMVT - MarketBeat
Citigroup Inc. Sells 75,860 Shares of Immunovant, Inc. $IMVT - MarketBeat
Immunovant, Inc. (IMVT) Analysts Raise Price Targets Following Q3 Earnings Update - Bitget
How Investors Are Reacting To Immunovant (IMVT) Narrower Q3 Loss and 2026 Autoimmune Trial Milestones - simplywall.st
Immunovant, Inc. (IMVT) Stock Analysis: A Compelling 48.2% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Immunovant (IMVT) COO executes 3,238-share sell-to-cover tax transaction - Stock Titan
Immunovant stock hits 52-week high at 28.32 USD By Investing.com - Investing.com Australia
Immunovant (NASDAQ:IMVT) Sets New 52-Week HighHere's What Happened - MarketBeat
Immunovant stock hits 52-week high at 28.32 USD - Investing.com
Precision Trading with Immunovant Inc. (IMVT) Risk Zones - Stock Traders Daily
Immunovant, Inc. (IMVT) Stock Analysis: Unpacking A 51% Potential Upside - DirectorsTalk Interviews
IMVT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? - AOL.com
Assessing Immunovant (IMVT) Valuation As Shares Deliver A 25% One Year Return - Yahoo Finance
What are Immunovant Inc.’s earnings expectationsOil Prices & Risk Managed Investment Strategies - mfd.ru
Aberdeen Group plc Has $15.83 Million Stock Position in Immunovant, Inc. $IMVT - MarketBeat
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT) - PR Newswire
Immunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Will Immunovant Inc. stock recover faster than marketTrade Analysis Report & Stepwise Swing Trade Plans - mfd.ru
What are analysts’ price targets for Immunovant Inc.Quarterly Trade Report & Capital Efficient Trading Techniques - mfd.ru
Technical Reactions to IMVT Trends in Macro Strategies - Stock Traders Daily
Why hedge funds are buying Immunovant Inc. stockMarket Trend Summary & Real-Time Volume Spike Alerts - mfd.ru
FY2026 EPS Forecast for Immunovant Increased by Analyst - MarketBeat
Finanzdaten der Immunovant Inc-Aktie (IMVT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):